title: Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial.
abstract: BACKGROUND
  Statin therapy has been reported to reduce the acute rejection rate following renal transplantation in a pilot study. The present study is the first randomized, double-blind and adequately powered study to examine the effect of statins on acute rejection of renal allografts.
  
  
  METHODS
  A total of 364 patients were randomly assigned to receive either fluvastatin 40 mg or placebo in combination with conventional cyclosporine-based immunosuppressive therapy. The primary end point was treated first acute rejection. Secondary end points included biopsy-proven rejection, histological severity of rejection, occurrence of steroid-resistant rejection, and serum creatinine at three months following transplantation.
  
  
  RESULTS
  Fluvastatin was well tolerated; no patients developed myositis or rhabdomyolysis. There was no difference in the acute rejection rate [86 (47.3%) fluvastatin vs. 87 (47.8%) placebo] and no significant difference in the severity of rejection, steroid resistant rejection or mean serum creatinine at three months (160 micromol/L vs. 160 micromol/L). Total cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and triglyceride levels increased following renal transplantation. With the exception of the increase in HDL-C, which was augmented, the increases in lipid parameters were significantly reduced by fluvastatin (total cholesterol +17.5% vs. 35.7%; LDL-C +6.3% vs. 46.7%; HDL-C +43.3% vs. 38.1%; triglyceride +52.2% vs 77.6%).
  
  
  CONCLUSIONS
  Contrary to the reported effects of statins, fluvastatin had no effect on the incidence or severity of acute rejection following renal transplantation. There were no increases in adverse events. A significant and potentially beneficial alteration in the lipid profile was observed in the early post transplant period. We conclude that fluvastatin may be used safely to correct dyslipidemia in patients with end-stage renal failure through the peri-transplant period.
authors.affiliation: Medical Department, National Hospital, 0027 Oslo, Norway. hallvard.holdaas@rikshospitalet.np
authors.forename: H
authors.initials: H
authors.lastname: Holdaas
authors.forename: A G
authors.initials: AG
authors.lastname: Jardine
authors.forename: D C
authors.initials: DC
authors.lastname: Wheeler
authors.forename: I B
authors.initials: IB
authors.lastname: Brekke
authors.forename: P J
authors.initials: PJ
authors.lastname: Conlon
authors.forename: B
authors.initials: B
authors.lastname: Fellstrøm
authors.forename: A
authors.initials: A
authors.lastname: Hammad
authors.forename: I
authors.initials: I
authors.lastname: Holme
authors.forename: H
authors.initials: H
authors.lastname: Isoniemi
authors.forename: R
authors.initials: R
authors.lastname: Moore
authors.forename: P A
authors.initials: PA
authors.lastname: Rowe
authors.forename: P
authors.initials: P
authors.lastname: Sweny
authors.forename: D A
authors.initials: DA
authors.lastname: Talbot
authors.forename: J
authors.initials: J
authors.lastname: Wadstrøm
authors.forename: Ø
authors.initials: Ø
authors.lastname: Østraat
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D001794:Blood Pressure; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012107:Research Design
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin